Continuous subcutaneous treatment with ND0612 may be more effective in managing motor fluctuations and other symptoms of PD than oral LD/CD, which often becomes less effective as the disease progresses.
The BeyoND study was an open-label, 1-year safety study in PD patients >30 years who were taking â„4 levodopa doses/day and â„1 other PD medications. To be included, patients were required to have â„2 hours of OFF time per day with predictable early-morning OFF periods. Participants received open-label ND0612 for either 16 or 24 hours. They took adjunct oral PD medications as needed. Mean time since PD diagnosis was 9.0±4.7 years, the mean duration of motor fluctuations was 5.3±4.2 years. Of the 214 PD patients enrolled, 124 were appointed to the 16-hour regimen, while 90 received the 24-hour regimen.
ND0612 was generally well tolerated. Local infusion-site reactions were transient and manageable. Reported systemic treatment-emergent adverse events (AEs) were consistent with those expected for levodopa. The most common treatment-emergent AEs were nodules, haematoma, and pain at the infusion site. Overall, less than a quarter of patients discontinued the study due to treatment-emergent AEs, and serious treatment-related AEs were rare. After 12 months, patients could continue treatment with ND0612; some of them are now in their fourth year. Of these participants, additional data is collected in the study extension.
- Isaacson S, et al. Abstract O3011, EAN 2020.
Posted on
Previous Article
« Directional DBS superior to omnidirectional DBS Next Article
Sleep disorders mark PD progression »
« Directional DBS superior to omnidirectional DBS Next Article
Sleep disorders mark PD progression »
Table of Contents: EAN 2020
Featured articles
Alzheimer's Disease and Other Dementias
Non-Alzheimerâs disease pathophysiology in the elderly
Novel genetic association with resistance to ERC tau deposition
Diastolic dysfunction novel risk factor for cognitive impairment
Epilepsy
Avoidable epilepsy-related mortality remains high
How genetic testing can contribute to epilepsy management
Cenobamate effective in focal epilepsy
Sustained seizure reductions with cannabidiol for Lennox-Gastaut syndrome
Prevalence of autoantibodies in epilepsy almost 10%
Parkinson's Disease
White matter matters in Parkinsonâs disease
Sleep disorders mark PD progression
Directional DBS superior to omnidirectional DBS
Stroke
Benefits of statins to prevent stroke outweigh risks
Extubation after thrombectomy: the sooner, the better
Thrombus location and length predictors of early neurological deterioration
Endovascular treatment in large vessel occlusion stroke patients treated with OAC
Early edoxaban may be safe after cardioembolic stroke
Headache and Pain
Small fibre pathology as biomarker for fibromyalgia
Migraine as a cyclical functional disorder
Reassuring real-world safety profile of 3 CGRP inhibitors
Long-term cardiovascular safety of erenumab
Real-world data for erenumab in Germany
Eptinezumab in chronic migraine and medication-overuse headache
Fremanezumab tolerability in cardiovascular patients with migraine
Effects of galcanezumab on health-related quality of life
Multiple Sclerosis
Imaging to evaluate remyelination and neuroprotection
Serum NfL predicts long-term clinical outcomes in MS
Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS
High NEDA rates after 2 years of ocrelizumab
Switching from natalizumab to moderate- versus high-efficacy DMT
Results of compounds in late stages of development
Alemtuzumab efficacy and safety data of over 9 years
Fampridine treatment results in routine clinical practice
Air pollution is a possible risk factor for MS
Neuromyelitis Optica Spectrum Disorder
Genetic association studies in NMOSD needed
Eculizumab in NMOSD: the PREVENT study
Long-term safety of satralizumab consistent with double-blind periods
Neuromuscular Disorders
Biomarkers predicting motor function in SMA
Sustained benefits of avalglucosidase alfa in late-onset Pompe disease
Efficacy and safety of rituximab in refractory MG corroborated
Related Articles
September 10, 2020
Fampridine treatment results in routine clinical practice
September 9, 2020
Early edoxaban may be safe after cardioembolic stroke
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy